Agenus (AGEN) Competitors $2.72 -0.11 (-3.89%) (As of 10:15 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGEN vs. VNDA, VSTM, LXRX, ACHV, RGLS, FBIO, SABS, CRIS, BOLT, and MTEMShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), and Molecular Templates (MTEM). These companies are all part of the "biotechnology" industry. Agenus vs. Vanda Pharmaceuticals Verastem Lexicon Pharmaceuticals Achieve Life Sciences Regulus Therapeutics Fortress Biotech SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Agenus (NASDAQ:AGEN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Which has more volatility and risk, AGEN or VNDA? Agenus has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Do institutionals & insiders have more ownership in AGEN or VNDA? 61.5% of Agenus shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 4.6% of Agenus shares are held by insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation & earnings, AGEN or VNDA? Vanda Pharmaceuticals has higher revenue and earnings than Agenus. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$160.43M0.41-$245.76M-$11.24-0.25Vanda Pharmaceuticals$190.86M1.46$2.51M-$0.28-17.07 Does the media favor AGEN or VNDA? In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than Agenus. MarketBeat recorded 5 mentions for Vanda Pharmaceuticals and 2 mentions for Agenus. Agenus' average media sentiment score of 0.45 beat Vanda Pharmaceuticals' score of 0.11 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend AGEN or VNDA? Agenus currently has a consensus price target of $10.00, suggesting a potential upside of 253.36%. Vanda Pharmaceuticals has a consensus price target of $15.50, suggesting a potential upside of 224.27%. Given Agenus' higher probable upside, equities analysts plainly believe Agenus is more favorable than Vanda Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor AGEN or VNDA? Vanda Pharmaceuticals received 70 more outperform votes than Agenus when rated by MarketBeat users. However, 69.29% of users gave Agenus an outperform vote while only 66.54% of users gave Vanda Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.29% Underperform Votes20730.71% Vanda PharmaceuticalsOutperform Votes53766.54% Underperform Votes27033.46% Is AGEN or VNDA more profitable? Vanda Pharmaceuticals has a net margin of -8.59% compared to Agenus' net margin of -145.89%. Agenus' return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% Vanda Pharmaceuticals -8.59%-3.02%-2.52% SummaryVanda Pharmaceuticals beats Agenus on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.39M$2.94B$5.15B$9.08BDividend YieldN/A1.90%5.12%4.25%P/E Ratio-0.2546.7387.1117.18Price / Sales0.41415.061,116.56117.12Price / CashN/A182.1043.2337.85Price / Book-0.363.894.794.78Net Income-$245.76M-$42.21M$120.55M$225.60M7 Day PerformanceN/A-2.36%-1.49%-1.36%1 Month Performance-15.27%1.83%13.65%0.20%1 Year Performance-81.90%16.78%28.61%15.30% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.5811 of 5 stars$2.72-3.9%$10.00+267.6%-81.9%$63.81M$160.43M-0.24389VNDAVanda Pharmaceuticals4.0511 of 5 stars$4.66+1.1%$15.50+232.6%+20.4%$271.72M$190.86M-16.54203VSTMVerastem3.7934 of 5 stars$4.74+5.8%$12.50+163.7%-49.3%$210.96M$10M-1.4050LXRXLexicon Pharmaceuticals1.6333 of 5 stars$0.82+1.0%$6.00+633.4%-45.4%$201.45M$5.23M-1.08285Analyst ForecastACHVAchieve Life Sciences1.6733 of 5 stars$4.11+0.2%$14.80+260.1%+0.5%$141.34MN/A-3.6320RGLSRegulus Therapeutics2.7506 of 5 stars$1.67+5.4%$10.80+548.6%+21.4%$109.06MN/A-1.4830Positive NewsFBIOFortress Biotech2.7747 of 5 stars$1.92-1.0%$13.67+611.8%-37.5%$53.00M$62.50M-0.63186News CoverageSABSSAB Biotherapeutics2.4302 of 5 stars$3.99-2.2%$12.40+210.8%+563.3%$36.82M$2.24M0.00140News CoverageGap UpCRISCuris2.52 of 5 stars$3.74+4.8%$23.00+515.0%-77.6%$31.67M$10.26M-0.4849BOLTBolt Biotherapeutics2.3073 of 5 stars$0.52-2.2%$3.50+577.8%-49.9%$19.76M$7.88M-0.31100MTEMMolecular Templates3.2069 of 5 stars$0.39-3.1%N/A-95.7%$2.55M$57.31M-0.1562Gap Down Related Companies and Tools Related Companies Vanda Pharmaceuticals Alternatives Verastem Alternatives Lexicon Pharmaceuticals Alternatives Achieve Life Sciences Alternatives Regulus Therapeutics Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Bolt Biotherapeutics Alternatives Molecular Templates Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGEN) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
